Ovid Therapeutics Inc. (1OT)

Profile

https://www.ovidrx.com

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, with an emphasis on epilepsies and other seizure-related neurological conditions. The company’s current pipeline centers on therapies designed to address significant unmet needs in central nervous system diseases, including OV329, a GABA-AT inhibitor in clinical development, and OV4071, an oral KCC2 activator being studied for select neuropsychiatric and neurological indications. Ovid Therapeutics works at the intersection of drug discovery and clinical development, advancing mechanism-based programs aimed at rare and complex disorders where treatment options remain limited. Its role in the market is to identify differentiated candidates for neurological and neuropsychiatric diseases and progress them through early-stage testing toward potential therapeutic use.